FDA Panel Advises Patient Consent With Power Morcellators To Warn Of Cancer Risk
This article was originally published in The Gray Sheet
Executive Summary
FDA’s Obstetrics and Gynecology Devices Advisory panel recommended a mandatory patient consent form, signed by both patient and physician, for use of laparascopic power morcellators during minimally invasive hysterectomy, and advised the morcellators not be used in individuals with suspected malignant sarcomas.
You may also be interested in...
Lawmakers Plan Bill In Response To GAO Power Morcellator Report
Several US House lawmakers are drafting a bill in response to a Government Accountability Office report finding that FDA's Medical Device Reporting system has shortcomings that may have missed adverse events for laparoscopic power morcellators. The devices have been linked to an increased risk of spreading cancer in women undergoing fibroid surgery.
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.